149 related articles for article (PubMed ID: 20552152)
1. [Hyperthermic intraperitoneal chemotherapy in the German DRG system. Analysis of case cost calculations of a maximum care university].
Kilian M; Hammerich R; Langelotz C; Raue W; Tsilimparis N; Rau B; Hartmann J
Chirurg; 2010 Nov; 81(11):1005-12. PubMed ID: 20552152
[TBL] [Abstract][Full Text] [Related]
2. Peritonectomy and hyperthermic intraperitoneal chemotherapy: cost analysis and sustainability.
Bagnoli PF; Cananzi FC; Brocchi A; Ardito A; Strada D; Cozzaglio L; Mussi C; Brusa S; Carlino C; Borrelli B; Alemanno F; Quagliuolo V
Eur J Surg Oncol; 2015 Mar; 41(3):386-91. PubMed ID: 25554680
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in a community setting: A cost-utility analysis of a hospital's initial experience and reflections on the health care system.
Naffouje SA; O'Donoghue C; Salti GI
J Surg Oncol; 2016 Apr; 113(5):544-7. PubMed ID: 26750613
[TBL] [Abstract][Full Text] [Related]
4. Cost Effectiveness of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Management of Colorectal Peritoneal Carcinomatosis.
Lee ZJ; Chia SL; Tan G; Soo KC; Teo CCM
Ann Surg Oncol; 2018 Aug; 25(8):2340-2346. PubMed ID: 29948417
[TBL] [Abstract][Full Text] [Related]
5. Cost-Effectiveness Analysis of Cytoreductive Surgery and HIPEC Compared With Systemic Chemotherapy in Isolated Peritoneal Carcinomatosis From Metastatic Colorectal Cancer.
Hamilton TD; MacNeill AJ; Lim H; Hunink MGM
Ann Surg Oncol; 2019 Apr; 26(4):1110-1117. PubMed ID: 30690682
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the cost-effectiveness of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (peritonectomy) at the St George Hospital peritoneal surface malignancy program.
Chua TC; Martin S; Saxena A; Liauw W; Yan TD; Zhao J; Lok I; Morris DL
Ann Surg; 2010 Feb; 251(2):323-9. PubMed ID: 20040853
[TBL] [Abstract][Full Text] [Related]
7. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal carcinomatosis. Preliminary results and cost from two centers in Greece.
Spiliotis J; Tentes AA; Vaxevanidou A; Korakianitis OS; Rogdakis A; Mirelis CG; Datsis AC; Kekelos S
J BUON; 2008; 13(2):205-10. PubMed ID: 18555466
[TBL] [Abstract][Full Text] [Related]
8. Cost analysis of the combined procedure of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC).
Baratti D; Scivales A; Balestra MR; Ponzi P; Di Stasi F; Kusamura S; Laterza B; Deraco M
Eur J Surg Oncol; 2010 May; 36(5):463-9. PubMed ID: 20363094
[TBL] [Abstract][Full Text] [Related]
9. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy with lobaplatin and docetaxel improves survival for patients with peritoneal carcinomatosis from abdominal and pelvic malignancies.
Wu HT; Yang XJ; Huang CQ; Sun JH; Ji ZH; Peng KW; Zhang Q; Li Y
World J Surg Oncol; 2016 Sep; 14(1):246. PubMed ID: 27633880
[TBL] [Abstract][Full Text] [Related]
10. Association between hospital finances, payer mix, and complications after hyperthermic intraperitoneal chemotherapy: deficiencies in the current healthcare reimbursement system and future implications.
Squires MH; Staley CA; Knechtle W; Winer JH; Russell MC; Perez S; Sweeney JF; Maithel SK; Staley CA
Ann Surg Oncol; 2015 May; 22(5):1739-45. PubMed ID: 25249258
[TBL] [Abstract][Full Text] [Related]
11. [Revenue and losses with vertebral augmentation under the G-DRG system 2012 - a comparison of supply costs in the context of vertebroplasty and kyphoplasty].
Krüger A; Wollny M; Oberkircher L; Bornemann R; Pflugmacher R
Z Orthop Unfall; 2012 Oct; 150(5):539-46. PubMed ID: 23076753
[TBL] [Abstract][Full Text] [Related]
12. Cost analysis of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy and the risk factors for their increased cost in a public insurance health care system - Single centre study.
Klos D; Riško J; Kriváčková D; Loveček M; Skalický P; Neoral Č; Melichar B; Mohelníková-Duchoňová B; Lemstrová R
Eur J Surg Oncol; 2020 Apr; 46(4 Pt A):607-612. PubMed ID: 31982207
[TBL] [Abstract][Full Text] [Related]
13. Analysis of operative morbidity in a single center initial experience with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Graziosi L; Mingrone E; Marino E; Cavazzoni E; Donini A
Tumori; 2014; 100(1):15-20. PubMed ID: 24675485
[TBL] [Abstract][Full Text] [Related]
14. Treatment of peritoneal carcinomatosis from ovarian cancer by surgical cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC).
Robella M; Vaira M; Marsanic P; Mellano A; Borsano A; Cinquegrana A; Sottile A; De Simone M
Minerva Chir; 2014 Feb; 69(1):27-35. PubMed ID: 24675244
[TBL] [Abstract][Full Text] [Related]
15. Cytoreductive surgery and intraoperative hyperthermic intraperitoneal chemotherapy with paclitaxel: a clinical and pharmacokinetic study.
de Bree E; Rosing H; Filis D; Romanos J; Melisssourgaki M; Daskalakis M; Pilatou M; Sanidas E; Taflampas P; Kalbakis K; Beijnen JH; Tsiftsis DD
Ann Surg Oncol; 2008 Apr; 15(4):1183-92. PubMed ID: 18239973
[TBL] [Abstract][Full Text] [Related]
16. Cost-analysis of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with peritoneal malignancy: An Australian perspective with global application.
McBride KE; Steffens D; Solomon MJ; Koh C; Ansari N; Young CJ; Moran B
Eur J Surg Oncol; 2021 Apr; 47(4):828-833. PubMed ID: 32972815
[TBL] [Abstract][Full Text] [Related]
17. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the treatment of peritoneal carcinomatosis: initial experience in Oaxaca, Mexico.
García-Matus R; Hernández-Hernández CA; Leyva-García O; Vásquez-Ciriaco S; Flores-Ayala G; Navarro-Hernández Q; Pérez-Bustamante G; Valencia-Mijares NM; Esquivel J
Am Surg; 2012 Sep; 78(9):942-6. PubMed ID: 22964201
[TBL] [Abstract][Full Text] [Related]
18. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal and gastrointestinal origin shows acceptable morbidity and high survival.
Hagendoorn J; van Lammeren G; Boerma D; van der Beek E; Wiezer MJ; van Ramshorst B
Eur J Surg Oncol; 2009 Aug; 35(8):833-7. PubMed ID: 19019619
[TBL] [Abstract][Full Text] [Related]
19. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) delivered via a modified perfusion system for peritoneal carcinomatosis of colorectal origin.
Cravioto-Villanueva A; Cavazos M; Luna-Perez P; Martinez-Gomez H; Ramirez ML; Solorzano J; Montiel H; Esquivel J
Surg Today; 2016 Aug; 46(8):979-84. PubMed ID: 27138212
[TBL] [Abstract][Full Text] [Related]
20. [Intraperitoneal hyperthermic perfusion chemotherapy in recurrent ovarian cancer].
Wydra D; Emerich J
Ginekol Pol; 2002 Nov; 73(11):1044-7. PubMed ID: 12722397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
